Search results for "Angiotensin"

showing 10 items of 396 documents

Sciences within European Young Researcher Community272The neuro-cardiac interaction defines an extracellular microdomain required for neurotrophic si…

2016

# 272 The neuro-cardiac interaction defines an extracellular microdomain required for neurotrophic signaling {#article-title-2} Purpose: Sympathetic neurons (SNs) innervate the myocardium with a defined topology that allows physiological modulation of cardiac activity. Limiting amounts of neurotrophins released by cardiac cells control SN viability and myocardial distribution, whose impairment has been described in a number of heart diseases (e.g. myocardial infarction, heart failure). Therefore, the fine control of cardiac innervation is crucial to ensure the physiological sympathetic function. It has been demonstrated that SNs directly interact with cardiomyocytes (CMs). Although it has b…

Genetically modified mousemedicine.medical_specialtybiologyTyrosine hydroxylasePhysiologyPhysiologyTropomyosin receptor kinase AAngiotensin IIEndocrinologymedicine.anatomical_structurePhysiology (medical)Internal medicinebiology.proteinmedicineMyocyteNeuronCardiology and Cardiovascular MedicineHomeostasisNeurotrophinCardiovascular Research
researchProduct

Fatal neuroinvasion and SARS-CoV-2 tropism in K18-hACE2 mice is partially independent on hACE2 expression

2022

ABSTRACTAnimal models recapitulating distinctive features of severe COVID-19 are critical to enhance our understanding of SARS-CoV-2 pathogenesis. Transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) under the cytokeratin 18 promoter (K18-hACE2) represent a lethal model of SARS-CoV-2 infection. The precise mechanisms of lethality in this mouse model remain unclear. Here, we evaluated the spatiotemporal dynamics of SARS-CoV-2 infection for up to 14 days post-infection. Despite infection and moderate pneumonia, rapid clinical decline or death of mice was invariably associated with viral neuroinvasion and direct neuronal injury (including brain and spinal neurons). Neuroinv…

Genetically modified mousevirusesMice TransgenicViremiaBiologyArticleVirusPathogenesisMiceVirologymedicineAnimalsHumansMelphalanTropismKeratin-18SARS-CoV-2COVID-19medicine.diseaseOlfactory bulbViral TropismInfectious DiseasesViral replicationtranslational animal model; comparative pathology; immunohistochemistry; in situ hybridization; viral pathogenesis; transmission electron microscopy; in vivo imagingImmunologyNeuropathogenesisAngiotensin-Converting Enzyme 2gamma-Globulins
researchProduct

The loss of muscle mass and sarcopenia: non hormonal intervention.

2011

Muscle aging is a key component of the increase in frailty in human populations. The generation of critical levels of power is a prerequisite to perform simple tasks of daily living, such as rising from a chair or climbing stairs. There is great scientific and social interest to determine which behaviors can lead to the maintenance of the muscle mass in young immobilized subjects and in the elderly. Several hormonal treatments have been proposed for the treatment of sarcopenia. However, the side effects associated to these treatments emphasize the need of finding non-toxic and non-hormonal treatments that help increase muscle strength, improve muscle function, and decrease the degree of dep…

Gerontologymedicine.medical_specialtyAgingSarcopeniaNon hormonalFrail ElderlyPopulationLongevityMuscle massBiochemistryBenzoatesLosartanAngiotensin Receptor AntagonistsEndocrinologyPhysical medicine and rehabilitationIntervention (counseling)GeneticsmedicineAnimalsHumansMuscle StrengthPPAR deltaTelmisartaneducationMolecular BiologyExerciseHeat-Shock ProteinsAgedAged 80 and overeducation.field_of_studybusiness.industryPublic healthTOR Serine-Threonine KinasesCell Biologymedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMuscle atrophyMuscular AtrophySarcopeniaMuscle strengthBenzimidazolesmedicine.symptombusinesshuman activitiesTranscription FactorsExperimental gerontology
researchProduct

Verlaufsbeobachtung von Patienten mit chronischer Aortenklappeninsuffizienz unter ACE-Hemmer-Therapie (Follow-up of patients with chronic severe aort…

1997

In dieser Untersuchung wurde der Einflus einer 3monatigen ACE-Hemmer-Therapie mit Cilazapril (2,5–5 mg) bei 13 Patienten mit chronischer Aortenklappeninsuffizienz spiroergometrisch und echokardiographisch untersucht. Nach 3monatiger Therapie sanken der linksventrikulare enddiastolische Diameter-Index von 3,5 auf 3,1 cm/m2 (p = 0,005), der linksventrikulare endsystolische Diameter-Index von 2,3 auf 2,0 cm/m2 (p = 0,005). Der Wallstress reduzierte sich von 174 auf 150 dyn/cm2 (p = 0,01). Die linksventrikulare Muskelmasse nahm um 14% ab, von anfangs 570 g (= 295 g/m2) auf 488 g (= 253 g/m2) (p < 0,05). Die von apikal gemesesene Jetflache reduzierte sich von 10,1 auf 8,1 cm2 (p < 0,05). Weder d…

Gynecologymedicine.medical_specialtyInsuficiencia aorticabiologybusiness.industryPeptidyl-Dipeptidase AFollow up studiesAngiotensin-converting enzymeCilazaprilValvula aorticamedicinebiology.proteinCardiology and Cardiovascular Medicinebusinessmedicine.drugZeitschrift f�r Kardiologie
researchProduct

Einflu� des Angiotensin II-Antagonisten Saralasin auf die H�modynamik bei Patienten mit renovaskul�rer Hypertonie

1977

Bei 7 Patienten mit Hypertonie bei einseitiger Nierenarterienstenose sowie einem Patienten mit Hypertonie bei einseitiger pyelonephritischer Schrumpfniere wurde der Einflus des Angiotensin II-Antagonisten Saralasin auf die Hamodynamik untersucht. Die Infusion von Saralasin fuhrte bei Patienten mit normalem Plasmarenin zu einer Erhohung des peripheren Gesamtwiderstands, bei erhohtem Renin zu einer Widerstandsabnahme. Bei extrem erhohten Reninwerten, die bei 3 Patienten unter forcierter Kochsalzverarmung beobachtet wurden, fuhrte Saralasin zu einem bedrohlichen Blutdruckabfall mit zusatzlicher starker Verminderung des Herzminutenvolumens und des zentralvenosen Drucks; die Herzfrequenz stieg d…

Gynecologymedicine.medical_specialtybusiness.industryGeneral MedicineAngiotensin IIchemistry.chemical_compoundchemistryDrug DiscoveryRenin–angiotensin systemmedicineMolecular MedicinebusinessGenetics (clinical)SaralasinKlinische Wochenschrift
researchProduct

Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.

2021

Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite end-point such as ICU admission and respiratory support, were explored.1,271 patients (22%) had a previous lung disease, mostly COPD. All-cause mortality occurred in 376 patients with lung disease (29.5%) and in 819 patients without (17.9%) (Previous lung disease is a risk factor for mortality in patients with COVID-19.…

HOPE-COVID-19 Health Outcome Predictive Evaluation for COVID-19Respiratory diseasesOriginal30-Day mortalityenfermedades respiratoriasACE2 angiotensin converting enzyme IIlaw.invention0302 clinical medicineCQ/HCQ chloroquine/hydroxychloroquinelawCOPDrespiratory diseasesPrognosisICU intensive care unitIntensive care unitSTROBE strengthening the reporting of observational studies in epidemiologypronósticomedicine.anatomical_structureEPOCCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialty30-day mortalityRT-PCR real time reverse transcriptase-polymerase chain reactionSARS-CoV-2 severe acute respiratory syndrome coronavirus 2WHO World Health OrganizationMERS middle east respiratory syndrome03 medical and health sciencesInternal medicinemedicineCOPDCOVID-19 2019 novel coronavirusRisk factorIQR interquartile rangeLungmortalidad a 30 díasbusiness.industryFEV1 forced expiratory volume in one secondCOVID-19Retrospective cohort studymedicine.diseaseHR hazard ratioICS inhaled corticosteroidsCI confidence intervalCoronavirusCOPD chronic obstructive pulmonary disease030228 respiratory systemRespiratory failureILD interstitial lung diseaseMiddle East respiratory syndromeprognosisHFNC high flow nasal cannulabusiness
researchProduct

Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress.

2014

Significance: Oxidative stress is a well established hallmark of cardiovascular disease and there is strong evidence for a causal role of reactive oxygen and nitrogen species (RONS) therein. Recent Advances: Improvement of cardiovascular complications by genetic deletion of RONS producing enzymes and overexpression of RONS degrading enzymes proved the involvement of these species in cardiovascular disease at a molecular level. Vice versa, overexpression of RONS producing enzymes as well as deletion of antioxidant enzymes was demonstrated to aggravate cardiovascular complications. Critical Issues: With the present overview we present and discuss different pathways how mitochondrial RONS inte…

Heart DiseasesPhysiologyClinical BiochemistryMitochondrionmedicine.disease_causeBiochemistrychemistry.chemical_compoundmedicineAnimalsHumansXanthine oxidaseMolecular BiologyGeneral Environmental Sciencechemistry.chemical_classificationInflammationReactive oxygen speciesNADPH oxidasebiologyNADPH OxidasesCell BiologyForum Review ArticlesAngiotensin IICell biologyMitochondriaNitric oxide synthaseCrosstalk (biology)Oxidative StressBiochemistrychemistrybiology.proteinGeneral Earth and Planetary SciencesReactive Oxygen SpeciesOxidation-ReductionOxidative stressSignal TransductionAntioxidantsredox signaling
researchProduct

Consensus on the management of hyperkalemia in patients with heart failure: Recommendations from the SEC-SEMI

2020

Abstract Use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure (HF) and reduced ejection fraction is associated with functional improvement, an increase in perceived quality of life, a reduction in the probability of cardiovascular death, and a decrease in the number of hospitalizations. Some of these drugs are also efficacious in patients with chronic kidney disease and albuminuria as well as in patients with resistant hypertension. Despite their numerous benefits, RAASi are associated with an increase in incidence of hyperkalemia, especially in patients with concomitant chronic kidney disease. Hyperkalemia is a common electrolyte disorder that is de…

Heart FailureMalemedicine.medical_specialtyConsensusEjection fractionHyperkalemiabusiness.industryIncidence (epidemiology)Angiotensin-Converting Enzyme InhibitorsGeneral Medicinemedicine.diseaseHeart failureConcomitantEmergency medicineQuality of LifemedicineAlbuminuriaHumansHyperkalemiaFemaleRenal Insufficiency Chronicmedicine.symptombusinessKidney diseaseElectrolyte DisorderRevista Clínica Española (English Edition)
researchProduct

Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind

2020

Heart Failuremedicine.medical_specialtybusiness.industrymedicine.diseaseRenin-Angiotensin SystemInternal medicineHeart failureCardiologyHumansMedicineNeprilysinCardiology and Cardiovascular MedicinebusinessNeprilysinRandomized Controlled Trials as TopicInternational Journal of Cardiology
researchProduct

Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia

2018

Hyperkalemia is one of the most common electrolyte disturbances, especially among some groups of patients, such as in those with chronic kidney disease, diabetes or heart failure. Hyperkalemia has been associated with increased risks of mortality, arrhythmias, hospitalization and costs, as well as the need to down titrate/discontinue renin-angiotensin-aldosterone system inhibitors (RAASIs), despite their well-known cardiovascular and nephroprotective benefits. Current potassium binders have limitations (slow onset of action, limited selectivity for potassium binding, risk of drug interactions or gastrointestinal intolerance). Sodium zirconium cyclosilicate (SZC) is a new potassium binder re…

Hyperkalemiabusiness.industrySilicatesPotassiumchemistry.chemical_elementPharmacologymedicine.diseaseRenin-Angiotensin Systemchemistry.chemical_compoundchemistryTolerabilityHeart failureDiabetes mellitusPotassiumHumansHyperkalemiaPotassium binderMedicineOnset of actionmedicine.symptombusinessKidney diseaseDrugs of Today
researchProduct